Ranbaxy Gets Tentative Nod for Galantamine

Ranbaxy Laboratories Ltd receives tentative approval from U.S. Food and Drug Administration to manufacture and market Galantamine Hydrobromide Tablets, 4, 8 and 12 mg (base). Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
India Infoline